Aktis Oncology

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Domain

aktisoncology.com

Employees

51-100

Last Funding

$175.0M

Founded

2020

Frequently Asked Questions

What technologies does Aktis Oncology use?+

Aktis Oncology uses 15 technologies including Contact Form 7, Google Analytics, Google Tag Manager.

What industry is Aktis Oncology in?+

Aktis Oncology operates in the Biotechnology industry.

Where is Aktis Oncology based?+

Aktis Oncology is headquartered in United States.

Need this data at scale?

Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.

Browse Datasets

Data last updated: June 2026